Amgen Projects Continued Increase in Biosimilars

Despite a two-year slowdown during the pandemic, biosimilars development programs are getting back on track, Amgen reported.

The company released a trend report on biosimilar approvals that shows that the FDA has approved 39 biosimilars since 2015 and manufacturers have launched 22 of these, only slowing down in 2020 and 2021.

The report notes a continued increase in the number of biosimilars in the FDA’s Biosimilar Development Program, moving from 77 programs in March 2019 to 96 programs in March 2022.

The first biosimilar was approved in the U.S. in 2015. The FDA currently lists 39 approved biosimilars.

Read the full trend report here: bit.ly/3MJ7bJK.